GSK bolsters oncology portfolio with $10.6bn Nuvalent
GSK is to acquire Boston-based clinical-stage oncology specialist Nuvalent for an equity value of approximately $10.6bn. This marks the British pharmaceutical giant’s largest transaction in over a decade. GSK will pay 124 dollars per share in cash for all outstanding Nuvalent common stock – a 40 per cent premium to Nuvalent’s previous closing stock price. The tender offer is scheduled…